Evolus (NASDAQ:EOLS) Shares Gap Down – Should You Sell?

Evolus, Inc. (NASDAQ:EOLS) shares gapped down prior to trading on Monday . The stock had previously closed at $13.69, but opened at $13.40. Evolus shares last traded at $13.46, with a volume of 48,769 shares changing hands.

Analysts Set New Price Targets

Several research analysts have issued reports on the company. Needham & Company LLC reiterated a “buy” rating and issued a $22.00 price target on shares of Evolus in a report on Friday, September 13th. HC Wainwright reissued a “buy” rating and issued a $27.00 price target on shares of Evolus in a research report on Thursday, November 7th. Cantor Fitzgerald restated an “overweight” rating on shares of Evolus in a report on Monday, September 16th. Finally, Barclays raised their price objective on shares of Evolus from $16.00 to $20.00 and gave the company an “overweight” rating in a research note on Friday, September 13th.

Evolus Stock Down 1.7 %

The company has a current ratio of 2.47, a quick ratio of 2.23 and a debt-to-equity ratio of 20.58. The stock has a market capitalization of $852.29 million, a PE ratio of -15.04 and a beta of 1.31. The stock’s fifty day simple moving average is $15.26 and its 200-day simple moving average is $13.88.

Insider Buying and Selling at Evolus

In other Evolus news, CFO Sandra Beaver sold 3,276 shares of the company’s stock in a transaction on Friday, September 6th. The stock was sold at an average price of $14.98, for a total value of $49,074.48. Following the completion of the transaction, the chief financial officer now owns 148,502 shares in the company, valued at $2,224,559.96. This represents a 2.16 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 6.10% of the company’s stock.

Hedge Funds Weigh In On Evolus

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Quest Partners LLC purchased a new position in Evolus in the second quarter valued at about $43,000. Quarry LP purchased a new position in Evolus in the second quarter valued at approximately $54,000. Profund Advisors LLC purchased a new stake in Evolus in the second quarter worth $130,000. Point72 Asset Management L.P. bought a new stake in shares of Evolus in the third quarter valued at $132,000. Finally, Arizona State Retirement System raised its stake in shares of Evolus by 9.4% in the second quarter. Arizona State Retirement System now owns 14,603 shares of the company’s stock valued at $158,000 after buying an additional 1,253 shares during the period. 90.69% of the stock is owned by hedge funds and other institutional investors.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.